Parkinson's Disease, Depression, Anhedonia
Conditions
Interventions
None listed
Sponsors
RadboudUMC Nijmegen, Department of Psychiatry
Eligibility
Inclusion criteria
Inclusion criteria: • A diagnosis of PD with <=5 years duration, defined as time since diagnosis made by a neurologist. • Subject can read and understand Dutch. • Subject is willing, competent, and able to comply with all aspects of the protocol • BDI score ?14 ánd meeting DSM-criteria for a depression including the criterium of a sad mood (depressed PD group) • BDI score <8 ánd in the 5 past years and/or currently not meeting DSM-criteria for a depression (non-depressed PD control group)
Exclusion criteria
Exclusion criteria: • Contraindications for MRI, e.g., claustrophobia, presence of an active implant, pacemaker, insulin pump, neurostimulator, ossicle prosthesis, pregnancy, and/or other medical device or other non-removable metal part incompatible with MRI. • Contraindications for PET e.g., inability to lie flat or lie still for the duration of the scan, claustrophobia (occasionally). • Use of medication or drugs with evident DAT-binding like methylphenidate, buproprion, amphetamines, cocaine that cannot be discontinued according to the PET-protocol. Note that we allow use of anti-depressants with the exception of those antidepressants with a high DAT binding defined as a relatively low Ki of <1000 (, i.e. for the Netherlands buproprion, duloxetine and sertraline). Moreover, we will exclude patients using antidepressants at higher than minimal effective dosages used for antidepressive effects when the Ki is <10000 (i.e. for the Netherlands amitryptiline, clomipramine, maprotiline, nortriptyline, fluoxetine, paroxetine). • Being diagnosed with dementia (defined as a Montreal Cognitive Assessment (MoCA) <21/30 (Dalymple-Alford 2010), assessed ON Parkinson medication). • Psychiatric diagnosis of bipolar disorder. • Presence of current psychotic symptoms.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences between (anhedonic and non-anhedonic) depressed PD patients and non-depressed PD patients in: •Baseline DAT-availability measured with PET •Functional connectivity from seeds with aberrant DAT-availability compared to non-depressed PD, in ON and OFF PD medication conditions. | — |
Secondary
| Measure | Time frame |
|---|---|
| Differences between (anhedonic and non-anhedonic) depressed PD patients and non-depressed PD patients in: • Effort-reward weighting on a behavioural computerized task -the effort-reward-choice-task (ERCT) - (Bonnelle 2016) to assess aspects of anhedonia in ON and OFF PD medication conditions. • fMRI-based BOLD signal when performing the ERCT during the decisional phase in ON and OFF PD medication conditions. • fMRI-based BOLD signal when performing a reinforcement learning task (Schmidt 2014) in ON and OFF PD medication conditions. • Subjective self-report measurements (self-report questionnaires Snaith-Hamilton Pleasure Scale (SHAPS) (Snaith 1995) and the Temporal Experience of Pleasure Scale (TEPS) (Gard 2006) to assess aspects of anhedonia, the Apathy Evaluation Scale (AES)-12PD to quantify the rate of apathy (Marin 1991, Beck Depression In-ventory (Beck 1961) and Inventory of Depressive Symptomatology (IDS) (Rush 1996) to quantify severity of depression, and the State-Trait Anxiety Questionnaire (STAI) (Spielberger 1983) and the Parkinson Anxiety Scale (Leentjens 2014) to quantify anxiety. | — |
Contacts
Public ContactMaria van Beek
RadboudUMC
Outcome results
None listed